Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
RNTX•FDA fast track designation for Lti-03
Rein Therapeutics Inc. received U.S. FDA fast track designation for Lti-03 in idiopathic pulmonary fibrosis.
- Rein Therapeutics is enrolling patients in the Phase 2 RENEW trial for Lti-03.
- Interim data are expected in the second half of 2026.
